APLS
Apellis Pharmaceuticals, Inc. · Healthcare
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.1M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Latest filing
May 14, 2026
DeLong Mark Jeffrey
Apellis Pharmaceuticals, Inc. (APLS) has 69 SEC Form 4 filings (190 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: May 14, 2026.
Inside the rolling window, 8 insiders at Apellis Pharmaceuticals, Inc. reported no open-market purchases and 28 open-market sales totaling $3.1M. The most active filer is General Counsel Watson David O. with 5 filings. Insiders have net sold $2.8M over the trailing 6 months. The most recent open-market filing is a sale of 368 shares by Chief Business & Strat Officer DeLong Mark Jeffrey, dated Feb 11, 2026, worth $8K.
- Industry:Biotechnology
- CEO:Cedric Francois
- Employees:705
- HQ:Waltham, MA, US
- IPO:2017-11-09
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Business & Strat Officer | Sale | 368 | $8K | Feb 13 | +89.1% | SEC ↗ | |
| Chief Business & Strat Officer | Sale | 3,371 | $73K | Jan 23 | +88.6% | SEC ↗ | |
| Chief Scientific Officer | Sale | 5,928 | $129K | Jan 23 | +88.6% | SEC ↗ | |
| Chief Medical Officer | Sale | 2,797 | $61K | Jan 23 | +88.6% | SEC ↗ | |
| General Counsel | Sale | 7,832 | $170K | Jan 23 | +88.6% | SEC ↗ | |
| VP/Chief Accounting Officer | Sale | 2,064 | $45K | Jan 23 | +88.6% | SEC ↗ | |
| Chief Financial Officer | Sale | 10,287 | $224K | Jan 23 | +88.6% | SEC ↗ | |
| Chief Technical Officer | Sale | 7,725 | $168K | Jan 23 | +88.6% | SEC ↗ | |
| Chief Executive Officer | Sale | 27,192 | $592K | Jan 23 | +88.6% | SEC ↗ | |
| Chief Medical Officer | Sale | 1,882 | $37K | Jan 21 | +95.8% | SEC ↗ | |
| VP/Chief Accounting Officer | Sale | 726 | $14K | Jan 21 | — | SEC ↗ | |
| Chief Technical Officer | Sale | 2,203 | $44K | Jan 21 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 909 | $18K | Jan 21 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 2,892 | $57K | Jan 21 | — | SEC ↗ | |
| Chief Business & Strat Officer | Sale | 1,334 | $26K | Jan 21 | — | SEC ↗ | |
| General Counsel | Sale | 2,475 | $49K | Jan 21 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 8,182 | $162K | Jan 21 | — | SEC ↗ | |
Deschatelets PascalFirst filing | Chief Scientific Officer | Sale | 2,277 | $51K | Jan 15 | — | SEC ↗ |
Chopas James GeorgeFirst filing | VP/Chief Accounting Officer | Sale | 873 | $19K | Jan 15 | — | SEC ↗ |
| Chief Financial Officer | Sale | 3,856 | $86K | Jan 15 | — | SEC ↗ | |
DeLong Mark JeffreyFirst filing | Chief Business & Strat Officer | Sale | 1,780 | $39K | Jan 15 | — | SEC ↗ |
Nicholson NurFirst filing | Chief Technical Officer | Sale | 2,618 | $58K | Jan 15 | — | SEC ↗ |
Francois CedricFirst filing | Chief Executive Officer | Sale | 10,186 | $226K | Jan 15 | — | SEC ↗ |
| General Counsel | Sale | 5,780 | $128K | Jan 15 | — | SEC ↗ | |
Baumal CarolineFirst filing | Chief Medical Officer | Sale | 3,020 | $77K | Jan 6 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does APLS have?
Apellis Pharmaceuticals, Inc. (APLS) has 69 SEC Form 4 filings (190 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: May 14, 2026.
When was the most recent SEC Form 4 filing for APLS?
The most recent Form 4 filing for APLS on Tracefour is dated May 14, 2026.
Who is the most active insider at APLS?
The most active SEC Form 4 filer at APLS in the rolling window is General Counsel Watson David O., with 5 filings.
What is the net insider flow at APLS over the last 6 months?
Over the trailing 180 days, insiders at APLS have net sold $2.8M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at APLS in the current window?
Inside the rolling window, insiders at APLS bought $0 and sold $3.1M based on SEC Form 4 filings.
Can I get alerts for APLS insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Apellis Pharmaceuticals, Inc. (APLS). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Apellis Pharmaceuticals, Inc. is in the Healthcare sector.